Description

Medtronic’s Acquisition Of Cathworks: Its SMARTEST Move in AI Cardiology?

Medtronic is poised to significantly deepen its interventional cardiology footprint with the potential acquisition of CathWorks, an Israel-based medtech innovator specializing in AI-driven coronary physiology assessment. After entering into a strategic partnership back in 2022, Medtronic recently announced it will exercise its option to acquire CathWorks for up to $585 million, pending regulatory approvals. CathWorks’ flagship FFRangio® System leverages artificial intelligence and computational modeling to derive Fractional Flow Reserve (FFR) measurements from standard angiograms without the need for invasive pressure wires or vasodilator drugs. This acquisition comes as Medtronic accelerates its financial performance, reporting robust Q2 results and guiding higher for FY26 revenue and EPS, driven by enterprise growth drivers such as PFA, Symplicity, Altaviva, and Hugo. Against this backdrop of commercial momentum, the addition of CathWorks could further cement Medtronic’s strategic position in coronary interventions and fuel a pipeline of high-margin, AI-enhanced diagnostic tools.